目的 观察左归丸联合阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效。方法 选取2014年2月—2016年2月在武汉市中医医院确诊的绝经后骨质疏松症患者152例，随机分为对照组和治疗组，每组各76例。对照组患者于早餐前30 min凉开水口服阿仑膦酸钠肠溶片，1片/次，1次/d；治疗组患者在对照组的基础上口服左归丸，9 g/次，2次/d。两组患者均连续治疗3个月。比较两组患者治疗前后临床疗效、骨密度变化，以及血清碱性磷酸酶（ALP）、骨钙素（BGP）和1，25-（OH）₂D₃水平。结果 治疗后，对照组和治疗组的总有效率分别为76.32%和92.11%，两组比较差异具有统计学意义（P< 0.05）。治疗后，两组患者腰L2～L4、双髋、右侧股骨颈的骨密度均较治疗前显著升高，同组比较差异具有统计学意义（P< 0.05）；且治疗组患者骨密度指标显著高于对照组，两组比较差异具有统计学意义（P< 0.05）。治疗后，两组患者ALP、1，25-（OH）₂D₃均显著升高，BGP显著降低，同组比较差异具有统计学意义（P< 0.05）；且治疗组ALP、1，25-（OH）₂D₃和BGP水平显著优于对照组，两组比较差异具有统计学意义（P< 0.05。结论 左归丸联合阿仑膦酸钠治疗绝经后骨质疏松患者比单用阿仑膦酸钠治疗的临床效果优势明显，且不良反应较轻，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Zuogui Pills combined with alendronate sodium in treatment of postmenopausal osteoporosis. Methods Patients (152 cases) with postmenopausal osteoporosis in Wuhan Hospital of Traditional Chinese Medicine from February 2014 to February 2016 were randomly divided into control and treatment groups, and each group had 76 cases. Patients in the control group were po administered with Alendronate Sodium Enteric-coated Tablets with cold boiled water 30 min before breakfast, 1 tablet/time, once daily. Patients in the treatment group were po administered with Zuogui Pills on the basis of the control group, 9 g/time, twice daily. Patients in two groups were treated for 3 months. After treatment, clinical efficacy, bone mineral density, ALP, BGP, and 1,25-(OH)₂D₃ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.32% and 92.11%, respectively, and there was difference between two groups (P < 0.05). After treatment, the bone mineral density of waist L2 to L4, bilateral hip, and right femoral neck in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the bone mineral density in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the ALP and 1,25-(OH)₂D₃ levels in two groups were significantly increased, BGP was significantly decreased, and there were differences in the same group (P < 0.05). And the levels of ALP, 1,25-(OH)₂D₃ and BGP in treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion The clinical effect of Zuogui Pills combined with alendronate sodium is more obvious than only alendronate sodium therapy in treatment of postmenopausal osteoporosis with mild adverse reactions, which has a certain clinical application value.